Zirafa Carmelina C, Cavaliere Ilenia, Ricciardi Sara, Romano Gaetano, Davini Federico, Aprile Vittorio, Melfi Franca
Minimally Invasive and Robotic Thoracic Surgery, Robotic Multispecialty Center of Surgery, University Hospital of Pisa, Pisa, Italy.
Division of Thoracic Surgery, Department of Surgical, Medical, Molecular, Pathology and Critical Care, University Hospital of Pisa, Pisa, Italy.
Surg Oncol. 2019 Mar;28:223-227. doi: 10.1016/j.suronc.2019.02.003. Epub 2019 Feb 6.
OBJECTIVE(S): Robotic lobectomy is becoming a widespread surgical procedure in NSCLC treatment, but data on oncologic outcomes is still lacking. The aim of this study was to analyze long term oncologic results of robotic lobectomy for non small lung cancer.
Clinical records of consecutive NSCLC patients underwent robotic major surgery, between January 2010 and December 2015, were collected and analyzed.
We analyzed data of 212 patients (127 male and 85 female), with a median age of 66.3 years. The median follow-up time was 40.3 months (range 4-83). The median disease free survival was 66.3 months. Free disease survival stage-correlated was 75.6 months for stage I, 42.3 months for stage II, 51.2 months for stage III and 10.3 months for stage IV. The median overall survival was 78.6 months. Overall survival stage-correlated was 82 months for stage I, 73.5 months for stage II, 61.4 months for stage III and 41.3 months for stage IV.
This study suggests high safety level, positive post-operative and oncologic outcomes for patients NSCLC underwent robotic major surgery, also in advanced stages.
机器人辅助肺叶切除术在非小细胞肺癌（NSCLC）治疗中已成为一种广泛应用的外科手术，但关于肿瘤学结局的数据仍然缺乏。本研究的目的是分析机器人辅助肺叶切除术治疗非小细胞肺癌的长期肿瘤学结果。
收集并分析2010年1月至2015年12月期间接受机器人辅助大手术的连续NSCLC患者的临床记录。
我们分析了212例患者的数据（男性127例，女性85例），中位年龄为66.3岁。中位随访时间为40.3个月（范围4 - 83个月）。中位无病生存期为66.3个月。I期的无病生存与分期相关的时间为75.6个月，II期为42.3个月，III期为51.2个月，IV期为10.3个月。中位总生存期为78.6个月。总生存与分期相关的时间I期为82个月，II期为73.5个月，III期为61.4个月，IV期为41.3个月。
本研究表明，接受机器人辅助大手术的NSCLC患者，即使处于晚期，也具有较高的安全性、良好的术后和肿瘤学结局。
